A Randomized Controlled Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations STEP
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms STEP
- 28 Oct 2018 Planned End Date changed from 30 Jun 2023 to 30 Oct 2023.
- 28 Oct 2018 Planned primary completion date changed from 30 Jun 2023 to 30 Oct 2023.
- 31 Aug 2018 Biomarkers information updated